Dudediligence.

Capricor Therapeutics, Inc

CAPRNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$2.3MSep ’24$11.1MDec ’24
Net income, by quarter
−$12.6MSep ’24−$7.1MDec ’24−$24.4MMar ’25−$25.9MJun ’25−$24.6MSep ’25−$30.2MDec ’25−$33.9MMar ’26−$40.7MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$244,898$2.6M$25.2M$22.3M$0.00
Operating income−$20.9M−$29.7M−$24.1M−$42.6M−$108.1M
Net income−$20.0M−$29.0M−$22.3M−$40.5M−$105.0M
Operating cash flow−$16.8M$4.9M−$25.6M−$40.0M−$69.8M
Free cash flow−$18.0M$2.9M−$26.9M−$41.2M−$72.7M
Cash$34.9M$9.6M$14.7M$11.3M$287.8M
Shares outstanding24.2M25.2M31.1M45.6M57.4M
CAPR fundamentals · DudeDiligence